Clinical Daily Summary
Clinical Daily Summary: What Happened on November 13, 2026
Melanoma vaccine cuts recurrence-or-death risk by 42% in Phase 3
Pelacarsen missed its Phase 3 primary endpoint. The day also brought early heart-failure and obesity data, plus longer-term findings in immune disease.
Today in brief
Merck and Moderna’s personalized vaccine, given with pembrolizumab after melanoma surgery, lowered the risk of recurrence or death by 42% versus pembrolizumab alone in a Phase 3 trial.12 Pelacarsen missed the primary endpoint in the Phase 3 HORIZON trial.3
Melanoma vaccine lowers recurrence-or-death risk by 42%
Merck and Moderna’s intismeran autogene lowered recurrence-or-death risk by 42% when added to pembrolizumab after surgery for high-risk melanoma.12 In the randomized trial of nearly 1,140 patients, two-year recurrence-free survival was 82% with the combination and 70% with pembrolizumab alone.1
The combination also reduced distant metastasis-or-death risk by 38%, with a prespecified analysis finding benefit in earlier- and later-stage disease.12 Common side effects included fever, injection-site pain and fatigue. Treatment stopped in 16.6% of the combination group and 9.5% of controls.12
The results were presented at the European Society for Medical Oncology meeting in October and published in The New England Journal of Medicine.12 Researchers and company executives said longer survival follow-up and more detailed immune findings are needed to guide treatment decisions and explain the vaccine’s effects.1 Merck and Moderna are preparing a Food and Drug Administration filing and anticipate possible approval in 2027.1
Pelacarsen misses HORIZON’s primary endpoint
Pelacarsen did not meet the primary endpoint in the Phase 3 HORIZON trial.3 The drug targets lipoprotein(a), a cardiovascular risk factor.3
Also worth knowing
-
Novartis reported sustained symptom improvements through 52 weeks with Rhapsido across three chronic inducible urticaria subtypes, with no new safety signals. The company plans regulatory applications for expanded use.4
-
Vasa Therapeutics said its early Phase 1c study of VS-041 in heart failure with preserved ejection fraction lowered NT-proBNP and identified serum endotrophin as a possible fibroinflammation marker. Further analyses are expected in early 2027.5
-
In Vivani Medical’s 20-person Phase 1 study, recipients of its semaglutide implant NPM-139 lost 0.79% of body weight over four weeks. No implant recipients had treatment-related adverse events.6
-
B
Wave Life Sciences reported one-year body-composition changes after a single 240 mg dose of WVE-007. Visceral and total fat and waist measurements fell versus placebo while lean mass was maintained. The interim findings have not been peer reviewed.7
-
B
Zai Lab said ZL-1503 inhibited an atopic dermatitis-related biomarker by at least 90% at week 12 in healthy volunteers given 200 to 1,000 mg. The study did not assess clinical efficacy.8
-
B
In Ionis’s open-label OASISplus extension, hereditary angioedema attack rates after two years were 95% below baseline among 83 participants. Rates among 64 patients who switched from prior prevention therapy were 71% below their previous-treatment baseline.9
-
In external validation, PERISCOPE models assigned in-hospital death risk correctly in 91% of comparisons, versus about 85% for GRACE 2.0. Researchers said prospective testing is still needed.10
-
Plozasiran maintained triglyceride-lowering activity alongside GLP-1 receptor agonists.11
-
Kerendia had similar effects on heart failure events and cardiovascular death across kidney-risk groups in patients with mildly reduced or preserved ejection fraction.12
Also published
- How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials Applied Clinical Trials
- AHA 2026: Tirzepatide Improves Key Biomarkers in Obesity-Related Heart Failure Clinical Trials Arena
- AHA26: Novo reveals baseline data for Phase III ARTEMIS trial Clinical Trials Arena
- AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence Pharmaceutical Technology
- AHA26: CRISPR gene editing shows promise in Phase Ib hypertriglyceridaemia trial Clinical Trials Arena
- AHA26: MAR001 highlights potential of ANGPTL4 inhibition for triglyceride lowering Clinical Trials Arena
- AMP 2026: Is Human Expertise Limiting AI Diagnostics? Inside Precision Medicine
- When Small Protocol Decisions Become Enrollment or Retention Barriers Pharmaceutical Executive
- Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial Applied Clinical Trials
- How Patients’ Use of AI Impact How Sponsors Communicate with Them Pharmaceutical Executive